GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from the first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.
Additional indications for nicotine replacement therapies the US Food and Drug Administration has said it will consider allowing haven't emerged in approved products.
Instead, the status quo persists. Even with GlaxoSmithKline PLC's new drug application for the first mouth spray delivery NRT...